WO2004096082A2 - Noninvasive blood analysis by optical probing of the veins under the tongue - Google Patents

Noninvasive blood analysis by optical probing of the veins under the tongue Download PDF

Info

Publication number
WO2004096082A2
WO2004096082A2 PCT/US2004/012758 US2004012758W WO2004096082A2 WO 2004096082 A2 WO2004096082 A2 WO 2004096082A2 US 2004012758 W US2004012758 W US 2004012758W WO 2004096082 A2 WO2004096082 A2 WO 2004096082A2
Authority
WO
WIPO (PCT)
Prior art keywords
blood
radiation
response
hemoglobin
technique
Prior art date
Application number
PCT/US2004/012758
Other languages
French (fr)
Other versions
WO2004096082A3 (en
Inventor
Rinat O. Esenaliev
Donald S. Prough
Original Assignee
The Board Of Regents Of The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Regents Of The University Of Texas System filed Critical The Board Of Regents Of The University Of Texas System
Priority to AU2004233870A priority Critical patent/AU2004233870B2/en
Priority to EP04750643A priority patent/EP1620002B1/en
Priority to US10/554,149 priority patent/US7430445B2/en
Priority to AT04750643T priority patent/ATE539674T1/en
Publication of WO2004096082A2 publication Critical patent/WO2004096082A2/en
Publication of WO2004096082A3 publication Critical patent/WO2004096082A3/en
Priority to US12/150,108 priority patent/US8352005B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0062Arrangements for scanning
    • A61B5/0068Confocal scanning
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0062Arrangements for scanning
    • A61B5/0066Optical coherence imaging
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14546Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/68Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/6813Specially adapted to be attached to a specific body part
    • A61B5/6814Head
    • A61B5/682Mouth, e.g., oral cavity; tongue; Lips; Teeth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14535Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring haematocrit

Definitions

  • the present invention relates to a novel system and method for non-invasive analysis of blood including blood components and analytes.
  • the present invention relates to a novel system and method for non- invasive analysis of blood including blood components and analytes, where the system is portable and pocket-sized and includes a probe having a tip designed to be placed in proximity to or in direct contact with tissue over a big vein on the underside of a patient's tongue, where the tip includes an excitation port through which an input signal generated by a signal generator subsystem impinges on a surface of tissue over the vein and a response port through which a response signal is received by and forwarded to a detector and analyzer or a detector/analyzer, which converts the response signal into a concentration of a blood component and/or a value of a blood parameter.
  • the present invention provides a system for non-invasive analysis of blood, including a probe having a tip designed to be placed in proximity to or in direct contact with tissue over a big vein on the underside of a patient's tongue, where the tip includes an excitation port through which an input signal generated by a signal generator subsystem impinges on a surface of the tissue over the vein and a response port through which a response signal is received by and forwarded to a detector and analyzer or a detector/analyzer, which converts the r esponse s ignal i nto concentration o f a b lood c omponent and/or a v alue o f a b lood parameter.
  • the present invention also provides a portable and pocket-sized system for non- invasive analysis of blood, including a probe having a tip designed to be placed in proximity to or in direct contact with tissue over a big vein on the underside of a patient's tongue, where the t ip includes an excitation p ort through which an input signal g enerated b y a s ignal generator subsystem impinges on a surface tissue over the vein and a response port through which a response signal is received by and forwarded to a detector and analyzer or a detector/analyzer, which converts the response signal into concentration of a blood component and/or a value of a blood parameter.
  • the present invention also provides a portable and pocket-sized system for non- invasive analysis of blood including an under the tongue apparatus comprising two side portions adapted to fit over teeth on each side of the lower jaw, a depressed portion between the two side portions including an excitation port through which an input signal generated by a signal generator subsystem impinges on a surface tissue over the vein and a response port through which a response signal is received by and forwarded to a detector and analyzer or a detector/analyzer, which converts the response signal into a concentration of a blood component and/or a value of a blood parameter.
  • the present invention also provides a system, including an excitation signal generator, a probe including a tip designed to be placed in proximity to or in contact with tissue over a big vein on the underside of a patient's tongue and having an excitation signal port connected to the generator via a signal transmission conduit and a response port connected to a detector which is in turn connected to an analyzer or a detector analyzer, where the analyzer converts the response signal into a concentration of a blood component and/or a value of a blood parameter.
  • the present invention also provides a portable and pocket-sized system for non- invasive glucose and/or cholesterol measuring and monitoring including a probe having a tip designed to be placed in proximity to or in direct contact with tissue over a big vein on the underside of a patient's tongue, where the tip includes an excitation port through which an input signal generated by a signal generator subsystem impinges on a tissue surface over the vein and a response port through which a response signal is received by and forwarded to a detector and analyzer or a detector/analyzer, which converts the response signal into concentrations of glucose and/or cholesterol in the blood.
  • the present invention also provides a portable and pocket-sized system for non- invasive hemoglobin, hematocrit, oxy-hemoglobin, deoxy-hemoglobin, carboxyhemoglobin, and/or glycosylated or glycated hemoglobin measuring and monitoring including a probe having a tip designed to be placed in proximity to or in direct contact with tissue over a big vein on the underside of a patient's tongue, where the tip includes an excitation port through which an input signal generated by a signal generator subsystem impinges on a tissue surface of the vein and a response port through which a response signal is received by and forwarded to a detector and analyzer or a detector/analyzer, which converts the response signal into concentrations of hemoglobin, hematocrit, oxy-hemoglobin, deoxy-hemoglobin, carboxyhemoglobin, and/or glycosylated or glycated hemoglobin in the blood.
  • the present invention provides a method for measuring and/or monitoring blood components and/or parameters including the steps of placing a tip of a probe having an excitation port and a response port in proximity to or in direct contact with tissue over a big vein on the underside of a patient's tongue. Once the tip is in proximity to or in contact with the tissue over the vein, an excitation signal is transmitted into the vein through the excitation port, where the excitation signal is generated by a signal generator com ected to the excitation port of the probe via a signal transmission conduit. After the excitation signal or input signal is transmitted into the vein, the response port receives a response signal and detects the response signal in a detector.
  • the present invention provides a method for measuring and/or monitoring blood components and/or parameters including the steps of placing a tip of a probe having an excitation port and a response port in proximity to or in direct contact with tissue over a big vein on the underside of a patient's tongue. Once the tip is in proximity to or in contact with the tissue over the vein, an excitation signal is transmitted into the vein through the excitation port, where the excitation signal is generated by a signal generator connected to the excitation port of the probe via a signal transmission conduit.
  • the response port receives a response signal directly through a detector that generates a detector signal which is transmitted via a detector signal conduit to an analyzer or via a response signal conduit to a detector/analyzer.
  • the analyzer converts the detected signal into a concentration of a blood component and/or a value of a blood parameter.
  • Figures 1A-C depict three preferred embodiments of apparatuses of this invention
  • Figures 1D-G depict three preferred embodiments of probes of this invention
  • Figures 1H depict another embodiments of apparatus of this invention
  • Figure 2 depicts another preferred embodiment of an apparatus of this invention, designed like an under tongue retainer
  • Figure 3 depicts a reflectance spectra measured from sheep blood at different THb
  • Figures 4 depicts a reflectance spectra measured from blood in vitro, the two veins (VI and V2), and tongue tissue (Tl, T2, and T3) on the underside of the tongue
  • Figure 5 depicts a reflectance signal from sheep blood vs. THb at 805 nm
  • Figures 6A-B depict a reflectance signal from circulating sheep blood vs.
  • Figures 7 A-B depict a reflectance spectra measured from sheep blood at different Thb and measurements performed by using a probe with 3-mm distance between irradiation and detection fibers through 0.15-mm glass slide;
  • Figures 8A-B depict a reflectance signal from sheep blood vs. THb at 805 nm (a) and 1300 nm (b), where measurements were performed through 0.15-mm glass slide;
  • Figures 9A-B depict a total diffuse reflectance spectra (R measured from sheep blood at different Thb, where measurements were performed by using an integrating sphere that collects all diffusively reflected light;
  • Figures 10A-B depict a total diffuse reflectance from sheep blood at 805 nm and 1300 nm (a) and the ratio R d (1300)/R d (805) (b) vs. THb, wheremeasurements were performed with the integrating sphere; and
  • Figures 11 A-B depict a total diffuse reflectance v.s wavelength from sheep blood for THb 14.8 g/dL.
  • the inventor has found that a novel system and method for non-invasive analysis of blood including blood components and analytes can be constructed and used.
  • Portable, pocket-sized devices can be developed for home and clinical use based on this technique permitting wide application for the apparatuses of this invention.
  • the technique is based on optical analysis of blood circulating in a big vein under a patient's tongue.
  • Light from an optical probe of an apparatus of this invention is directed into one of these veins by bringing a probe tip in close proximity to or in contact with the surface of tongue tissue above the vein, i.e., the tip of the probe is brought into proximity to or in contact with epithelial tissue overlying the big veins beneath the surface of the underside of the tongue.
  • Non-contact analysis may ultimately be the preferred method from a medical and practical point of view because the tip does not make contact with the tissue, thereby reducing the possibility of infections.
  • the emitted light interacts with blood flowing through the vein, producing a signal.
  • the produced or output signal is received or received and measured by the probe, where the output signal will depend on optical properties of the blood.
  • the optical properties of the blood are related to concentrations of blood components. Because the tissues between the probe tip and blood circulating in the vein is very thin, the output signals received by the apparatuses of this invention have minimal influences from the intervening tissue (i.e., minimal background signals) caused by light scattering and absorption in the intervening tissue.
  • the term "in proximity to” means that the probe tip is sufficiently close to the surface tissue of the underside of the tongue of a patient to produce a response signal of sufficient intensity to be measured. Generally, the distance is between about 10 mm and about 1mm, with distances between about 5 mm and 1 mm being preferred. However, larger or smaller distances can be used as well provided an analyzable signal can be detected.
  • the term "in contact with” means that the probe tip actually makes physical contact with the tissue of the underside of the patient's tongue.
  • the excitation light can be in the near infrared (wavelength range from about 760 to about 2,500 nm), the visible (wavelength range from about 400 to about 760 nm), or the near UV (from about 250 to about 400 nm) portions of the electromagnetic spectrum. These portions of the electromagnetic spectrum would have insignificant background signals due to relatively low scattering and absorption in the intervening tissue compared with light from other spectral ranges.
  • the method and system of this invention can utilize any optical detection technique or hybrid detection techniques including, but not limited to, reflectance techniques, confocal techniques, scanning confocal techniques, polarization techniques, interferometry techniques, optoacoustic techniques, low coherence reflectometry techniques, techniques based on speckle measurements, or similar techniques or mixtures or combinations thereof.
  • One preferred application of this invention is noninvasive measurement of hemoglobin concentration and/or hematocrit in blood.
  • Other applications of the systems and methods of this invention include, without limitation, noninvasive measurements of glucose and/or cholesterol concentrations in blood and potentially can be used for measuring oxy-, deoxy-, carboxyhemoglobin, and/or glycosylated hemoglobin concentrations in blood.
  • Other applications include, without limitation, measuring or monitoring analytes, drugs, exogenous substances, and/or blood parameters (such as pH).
  • This technique can be used for blood analysis of healthy population and patients with various diseases and disorders including critically ill patients.
  • a preferred embodiment of a system of this invention is shown to include a probe 102 having a tip 104, which is in proximity to or in contact with a surface tissue 106 over a vein 108 of an underside 109 of a patient's tongue 110.
  • the system 100 also includes a light delivery subsystem 112 and detection/analysis subsystem 114.
  • the light delivery subsystem 112 terminates in the probe tip 104 at a light outlet or port 116, while the detection/analysis subsystem 114 begins in the tip 104 at an output or response signal inlet or port 118.
  • the light delivery subsystem 112 includes a light source 120 and a light conduit 122 terminating at the light outlet 1 16.
  • the light conduit 122 is an optical fiber or optical fiber bundle and the light source 120 is a laser or filtered broad spectrum light source (e.g., lamp).
  • the detection/analysis subsystem 114 includes a detector 124, an analyzer unit 126 and a signal conduit 128 interconnecting the detector 124 and the analyzer 126.
  • the detector 124 can be located in the tip 104 as shown in Figure 1A, in the probe 102 as shown in Figure IB or in the analyzer unit 126 as shown in Figure 1C.
  • the output signal forwarded to the analyzer 126 can be optical and/or acoustic, if the detector 124 is located in the analyzer 126 or electrical, if the detector 124 is located in the probe 104.
  • the light conduit 122 is a single optical fiber, while the signal conduit 128 includes six optical fibers surrounding the light conduit 122 for a cylindrical probe 102 and circular probe tip 104.
  • the light conduit 122 includes four fibers and the signal conduit 128 includes four optical fibers surrounding the light conduit 122 arranged side by side for an oval shaped probe 102 and tip 104.
  • the light conduit 122 includes four fibers and the signal conduit 128 includes four optical fibers surrounding the light conduit 122 arranged intermixed for a rectangular probe 102 and probe tip 104.
  • the light conduit 122 includes one fiber and the signal conduit 128 includes tliree optical fibers surrounding the light conduit 122 for a triangular probe 102 and probe tip 104.
  • the system 100 works by placing the probe tip 104 in contact with the surface tissue 106 over the vein 108.
  • the probe 102 also includes a finger grip 103 for better control of the probe tip placement.
  • the light delivery system 112 is then activated, turned on, and excitation radiation travels from the light source 120 through the light conduit 122 and out the light outlet 116 in the probe tip 104.
  • the excitation radiation then propagates through the surface tissue 106, a relatively thin tissue layer, and into the vein 108 where a response signal is produced.
  • the response signal then enters the signal port 118 where it is either detected by the detector 124 in the probe 102 or the probe tip 104 or travels down the signal conduit 128 to the detector 124 associated with the analyzer unit 126.
  • the detector 124 converts the signal into a detector response and the analyzer converts the response into a concentration of a blood component and/or a value of a blood parameter.
  • a second embodiment of an apparatus of this invention is shown to include a first teeth engaging side section 202a, a second teeth engaging side section 202b, a first and a second downwardly extending sections 204a&b and a middle section 206 bridging the two downwardly extending sections 204a&b adapted to contact the underside of a patient's tongue (not shown).
  • the middle section 206 includes two emitters 208a&b and two receivers 210a&b.
  • Extending from the two emitters 208a&b and the two detectors 210a&b are light conduits 212a&b, shown here as two optical fibers 214a&b terminating at the emitters 208a&b, and signal conduits (light or sound) 216a&b, also shown here as to optical fibers 218a&b terminating at the receivers.
  • the light conduits 212a&b are connected to a light source 220, while the signal conduits 216a&b are connected to a detector/analyzer 222.
  • tissue Most tissues are strongly scattering media in the visible and near-IR spectral range.
  • Three major optical parameters are responsible for distribution of light in tissues: 1) the absorption coefficient ( ⁇ ; 2) the scattering coefficient ( ⁇ s ); and 3) the effective attenuation ( ⁇ eff ) coefficient.
  • the effective attenuation coefficient ( ⁇ eff ) is related to ⁇ a , ⁇ s , and the anisotropy factor (g) thusly:
  • ⁇ s (l-g) is the reduced scattering coefficient, ⁇ s ' [1].
  • Light penetration depth in tissues is defined as l/ ⁇ eff .
  • Absorption and reduced scattering coefficients of tissues are moderate in the visible spectral range and low in the near-IR spectral range (from 600 to 1600 nm), which results in deeper penetration of visible and especially near-IR radiation compared with that of other parts of the spectrum.
  • Application of visible or near-IR radiation will allow insignificant attenuation of light in the thin tissues between the vein on the underside of the tongue and the probe.
  • Hemoglobin has a high absorption coefficient in the visible and near-IR spectral range that is dependent on hemoglobin oxygen saturation (the ratio of oxyhemoglobin to total hemoglobin (THb) [1].
  • the tissue between the vein on the underside of the tongue and the probe is optically thin in the visible and near IR spectral ranges because: ⁇ eff x L « 1 due to relatively low ⁇ eff (- 1 - 5 cm “1 ) and small L (-0.01-0.02 cm), hi contrast, blood in the vein is optically thick: u- e ff, b i ood x L b i ood >:> 1 because ⁇ eff ⁇ b ⁇ 0od * s high (-10 cm "1 ) and L is about 2 to 3 mm. Attenuation is the tissue is insignificant and all signal will be from blood.
  • FIG. 3 shows diffuse reflectance spectra obtained from sheep blood at different total hemoglobin concentration (THb) through the cylindrical wall (thickness 0.8 mm) of a 10-mL syringe. Blood with an initial THb of 8.2 g/dL, oxygenation of 56%, and volume of 5 mL was progressively diluted with saline with increments of 0.5 mL. The final concentration was 4.1 g/dL.
  • the spectra were obtained with a portable (pocket size) spectrometer (range from 600 to 1180 nm) operated with a laptop computer.
  • This range included the isobestic wavelength of 805 nm, where oxy- and deoxyhemoglobin have the same absorption coefficient. Therefore, variations of blood oxygenation do not influence the accuracy of THb measurement at this wavelength.
  • the sample was irradiated by a tungsten lamp (the lamp and its power supply are compact: pocket size; designed for this spectrometer) through a reflection probe combining one 0.4-mm illumination fiber and six 0.4-mm fibers around it for detection of the reflectance signal.
  • the system was calibrated with a reflectance standard with 25% reflectivity. The standard is being widely used for calibration of optical spectroscopic instruments in a wide spectral range that includes ultraviolet (UV), visible, and near infra-red (near-IR) spectral ranges.
  • UV ultraviolet
  • visible visible
  • near-IR near infra-red
  • the diffuse reflectance signal is due to light scattering from red blood cells in blood. All spectra had: (1) a minimum at 760 nm due to the absorption peak (maximum of absorption) at this wavelength for deoxygenated hemoglobin and (2) low intensity at 600 nm due to strong absorption by hemoglobin. The spectra were dependent on THb. In this geometry of irradiation, the reflectance signal first increased and then decreased with dilution. [0044] Since the tissues between the blood circulating in the tongue vein and the probe are very thin (01.-0.2 mm), they are optically thin in the visible and near-IR spectral ranges due to low tissue absorption.
  • Figure 4 shows representative reflectance spectra measured: (1) in vitro from blood; (2) in vivo from the two big veins (VI and V2) on underside of the tongue of a healthy volunteer; and (3) at three locations: right, left and middle part of the underside of the tongue (Tl, T2, and T3, respectively). It is clearly seen that the spectra measured from the veins are similar to that of blood. As in pure blood, the spectra have minimum values at 760 nm and low intensity at 600 nm. The spectra measured from the tongue tissue are different from that of pure blood: high intensity at 600 nm and no minimum at 760 nm.
  • the reflectance signal at a given THb and oxygenation is dependent on wavelength and the reflectance probe configuration.
  • Figure 5 shows the reflectance signal at 805 nm vs. THb for the spectra presented in Figure 3. The signal is linearly dependent on THb from 4.1 to 6.3 g/dL.
  • Another set of experiments was performed with circulating centrifuged sheep blood. Typically, THb of sheep blood (6-9 g/dL) is lower than that of human blood (ll-16 g/dL) . By using the centrifuge one can obtain blood with THb up to 14-16 g/dL (typical for human blood). To simulate the gap of 0.1 -0.2 mm between the veins and the probe, we used a thin (0.15 mm) microscopic glass slide cover.
  • Figure 6A and 6B show reflectance spectra obtained from blood (initial THb of 14.1 g/dL) with the two spectrometers, respectively. Both spectra were measured simultaneously by using a fiber-optic splitter attached to the detection fibers of the probe. One can see that the spectra are dependent on THb in both spectral ranges. Reflectance signals are presented as a function of THb for 805 and 1300 nm in Figure 7A. The dependence was linear up to approximately 8 and 9 g/dL for the wavelengths of 805 and 1300 nm, respectively. At 1450 nm, it was linear up to 10 g/dL as shown in Figure 7B.

Abstract

A method for analysis of blood components or parameters is disclosed where a probe (102) having an excitation outlet (116) and a response inlet (118) is placed in proximity to or in contact with a tissue of an underside of a patient's tongue over a big vein (108) in the tongue so that an excitation signal exits the outlet, produces a response which enters the inlet for detection and analysis.

Description

NONINVASIVE BLOOD ANALYSIS BY OPTICAL PROBING OF THE VEINS UNDER THE TONGUE
ASSIGNEE: The Board of Regents of the University of Texas System
RELATED APPLICATIONS
[0001] This PCT Application, under United States law, claims provisional priority to United States Provisional Patent Application Serial No. 60/465,134, filed 24 April 2003.
BACKGROUND OF THE INVENTION
1. Field of the Invention
[0002] The present invention relates to a novel system and method for non-invasive analysis of blood including blood components and analytes.
[0003] More particularly, the present invention relates to a novel system and method for non- invasive analysis of blood including blood components and analytes, where the system is portable and pocket-sized and includes a probe having a tip designed to be placed in proximity to or in direct contact with tissue over a big vein on the underside of a patient's tongue, where the tip includes an excitation port through which an input signal generated by a signal generator subsystem impinges on a surface of tissue over the vein and a response port through which a response signal is received by and forwarded to a detector and analyzer or a detector/analyzer, which converts the response signal into a concentration of a blood component and/or a value of a blood parameter.
2. Description of the Related Art
[0004] Analysis of blood is needed for diagnostic and management of various diseases and conditions as well as for screening of healthy population. Current techniques and systems for blood analysis are invasive, require blood sampling, and cannot be performed in real time or continuously. At present, blood is usually analyzed in clinical laboratories after talcing blood samples with invasive techniques.
[0005] Thus, there is a need in the art for a technique and system for noninvasive analysis of blood that would benefit a large population of patients and healthy people as well.
SUMMARY OF THE INVENTION [0006] The present invention provides a system for non-invasive analysis of blood, including a probe having a tip designed to be placed in proximity to or in direct contact with tissue over a big vein on the underside of a patient's tongue, where the tip includes an excitation port through which an input signal generated by a signal generator subsystem impinges on a surface of the tissue over the vein and a response port through which a response signal is received by and forwarded to a detector and analyzer or a detector/analyzer, which converts the r esponse s ignal i nto concentration o f a b lood c omponent and/or a v alue o f a b lood parameter.
[0007] The present invention also provides a portable and pocket-sized system for non- invasive analysis of blood, including a probe having a tip designed to be placed in proximity to or in direct contact with tissue over a big vein on the underside of a patient's tongue, where the t ip includes an excitation p ort through which an input signal g enerated b y a s ignal generator subsystem impinges on a surface tissue over the vein and a response port through which a response signal is received by and forwarded to a detector and analyzer or a detector/analyzer, which converts the response signal into concentration of a blood component and/or a value of a blood parameter.
[0008] The present invention also provides a portable and pocket-sized system for non- invasive analysis of blood including an under the tongue apparatus comprising two side portions adapted to fit over teeth on each side of the lower jaw, a depressed portion between the two side portions including an excitation port through which an input signal generated by a signal generator subsystem impinges on a surface tissue over the vein and a response port through which a response signal is received by and forwarded to a detector and analyzer or a detector/analyzer, which converts the response signal into a concentration of a blood component and/or a value of a blood parameter.
[0009] The present invention also provides a system, including an excitation signal generator, a probe including a tip designed to be placed in proximity to or in contact with tissue over a big vein on the underside of a patient's tongue and having an excitation signal port connected to the generator via a signal transmission conduit and a response port connected to a detector which is in turn connected to an analyzer or a detector analyzer, where the analyzer converts the response signal into a concentration of a blood component and/or a value of a blood parameter.
[0010] The present invention also provides a portable and pocket-sized system for non- invasive glucose and/or cholesterol measuring and monitoring including a probe having a tip designed to be placed in proximity to or in direct contact with tissue over a big vein on the underside of a patient's tongue, where the tip includes an excitation port through which an input signal generated by a signal generator subsystem impinges on a tissue surface over the vein and a response port through which a response signal is received by and forwarded to a detector and analyzer or a detector/analyzer, which converts the response signal into concentrations of glucose and/or cholesterol in the blood.
[0011] The present invention also provides a portable and pocket-sized system for non- invasive hemoglobin, hematocrit, oxy-hemoglobin, deoxy-hemoglobin, carboxyhemoglobin, and/or glycosylated or glycated hemoglobin measuring and monitoring including a probe having a tip designed to be placed in proximity to or in direct contact with tissue over a big vein on the underside of a patient's tongue, where the tip includes an excitation port through which an input signal generated by a signal generator subsystem impinges on a tissue surface of the vein and a response port through which a response signal is received by and forwarded to a detector and analyzer or a detector/analyzer, which converts the response signal into concentrations of hemoglobin, hematocrit, oxy-hemoglobin, deoxy-hemoglobin, carboxyhemoglobin, and/or glycosylated or glycated hemoglobin in the blood. [0012] The present invention provides a method for measuring and/or monitoring blood components and/or parameters including the steps of placing a tip of a probe having an excitation port and a response port in proximity to or in direct contact with tissue over a big vein on the underside of a patient's tongue. Once the tip is in proximity to or in contact with the tissue over the vein, an excitation signal is transmitted into the vein through the excitation port, where the excitation signal is generated by a signal generator com ected to the excitation port of the probe via a signal transmission conduit. After the excitation signal or input signal is transmitted into the vein, the response port receives a response signal and detects the response signal in a detector.
[0013] The present invention provides a method for measuring and/or monitoring blood components and/or parameters including the steps of placing a tip of a probe having an excitation port and a response port in proximity to or in direct contact with tissue over a big vein on the underside of a patient's tongue. Once the tip is in proximity to or in contact with the tissue over the vein, an excitation signal is transmitted into the vein through the excitation port, where the excitation signal is generated by a signal generator connected to the excitation port of the probe via a signal transmission conduit. After the excitation signal or input signal is transmitted into the vein, the response port receives a response signal directly through a detector that generates a detector signal which is transmitted via a detector signal conduit to an analyzer or via a response signal conduit to a detector/analyzer. Once the signal has been detected, the analyzer converts the detected signal into a concentration of a blood component and/or a value of a blood parameter.
DESCRIPTION OF THE DRAWINGS [0014] The invention can be better understood with reference to the following detailed description t ogether w ith the appended illustrative drawings in which like elements are numbered the same:
[0015] Figures 1A-C depict three preferred embodiments of apparatuses of this invention; [0016] Figures 1D-G depict three preferred embodiments of probes of this invention; [0017] Figures 1H depict another embodiments of apparatus of this invention; [0018] Figure 2 depicts another preferred embodiment of an apparatus of this invention, designed like an under tongue retainer;
[0019] Figure 3 depicts a reflectance spectra measured from sheep blood at different THb; [0020] Figures 4 depicts a reflectance spectra measured from blood in vitro, the two veins (VI and V2), and tongue tissue (Tl, T2, and T3) on the underside of the tongue; [0021] Figure 5 depicts a reflectance signal from sheep blood vs. THb at 805 nm; [0022] Figures 6A-B depict a reflectance signal from circulating sheep blood vs. THb at 805, 1300, and 1450 nm and measurements performed through 0.15-mm glass slide; [0023] Figures 7 A-B depict a reflectance spectra measured from sheep blood at different Thb and measurements performed by using a probe with 3-mm distance between irradiation and detection fibers through 0.15-mm glass slide;
[0024] Figures 8A-B depict a reflectance signal from sheep blood vs. THb at 805 nm (a) and 1300 nm (b), where measurements were performed through 0.15-mm glass slide; [0025] Figures 9A-B depict a total diffuse reflectance spectra (R measured from sheep blood at different Thb, where measurements were performed by using an integrating sphere that collects all diffusively reflected light;
[0026] Figures 10A-B depict a total diffuse reflectance from sheep blood at 805 nm and 1300 nm (a) and the ratio Rd(1300)/Rd(805) (b) vs. THb, wheremeasurements were performed with the integrating sphere; and
[0027] Figures 11 A-B depict a total diffuse reflectance v.s wavelength from sheep blood for THb 14.8 g/dL. DETAILED DESCRIPTION OF THE INVENTION
[0028] The inventor has found that a novel system and method for non-invasive analysis of blood including blood components and analytes can be constructed and used. Portable, pocket-sized devices can be developed for home and clinical use based on this technique permitting wide application for the apparatuses of this invention.
[0029] The technique is based on optical analysis of blood circulating in a big vein under a patient's tongue. Light from an optical probe of an apparatus of this invention is directed into one of these veins by bringing a probe tip in close proximity to or in contact with the surface of tongue tissue above the vein, i.e., the tip of the probe is brought into proximity to or in contact with epithelial tissue overlying the big veins beneath the surface of the underside of the tongue. Non-contact analysis may ultimately be the preferred method from a medical and practical point of view because the tip does not make contact with the tissue, thereby reducing the possibility of infections. The emitted light interacts with blood flowing through the vein, producing a signal. The produced or output signal is received or received and measured by the probe, where the output signal will depend on optical properties of the blood. The optical properties of the blood are related to concentrations of blood components. Because the tissues between the probe tip and blood circulating in the vein is very thin, the output signals received by the apparatuses of this invention have minimal influences from the intervening tissue (i.e., minimal background signals) caused by light scattering and absorption in the intervening tissue.
[0030] The term "in proximity to" means that the probe tip is sufficiently close to the surface tissue of the underside of the tongue of a patient to produce a response signal of sufficient intensity to be measured. Generally, the distance is between about 10 mm and about 1mm, with distances between about 5 mm and 1 mm being preferred. However, larger or smaller distances can be used as well provided an analyzable signal can be detected. The term "in contact with" means that the probe tip actually makes physical contact with the tissue of the underside of the patient's tongue.
[0031] The excitation light can be in the near infrared (wavelength range from about 760 to about 2,500 nm), the visible (wavelength range from about 400 to about 760 nm), or the near UV (from about 250 to about 400 nm) portions of the electromagnetic spectrum. These portions of the electromagnetic spectrum would have insignificant background signals due to relatively low scattering and absorption in the intervening tissue compared with light from other spectral ranges.
[0032] The method and system of this invention can utilize any optical detection technique or hybrid detection techniques including, but not limited to, reflectance techniques, confocal techniques, scanning confocal techniques, polarization techniques, interferometry techniques, optoacoustic techniques, low coherence reflectometry techniques, techniques based on speckle measurements, or similar techniques or mixtures or combinations thereof. [0033] One preferred application of this invention is noninvasive measurement of hemoglobin concentration and/or hematocrit in blood. Other applications of the systems and methods of this invention include, without limitation, noninvasive measurements of glucose and/or cholesterol concentrations in blood and potentially can be used for measuring oxy-, deoxy-, carboxyhemoglobin, and/or glycosylated hemoglobin concentrations in blood. Other applications include, without limitation, measuring or monitoring analytes, drugs, exogenous substances, and/or blood parameters (such as pH).
[0034] This technique can be used for blood analysis of healthy population and patients with various diseases and disorders including critically ill patients.
[0035] Referring now to Figures 1A-D, a preferred embodiment of a system of this invention, generally 100, is shown to include a probe 102 having a tip 104, which is in proximity to or in contact with a surface tissue 106 over a vein 108 of an underside 109 of a patient's tongue 110. The system 100 also includes a light delivery subsystem 112 and detection/analysis subsystem 114. The light delivery subsystem 112 terminates in the probe tip 104 at a light outlet or port 116, while the detection/analysis subsystem 114 begins in the tip 104 at an output or response signal inlet or port 118. The light delivery subsystem 112 includes a light source 120 and a light conduit 122 terminating at the light outlet 1 16. Preferably, the light conduit 122 is an optical fiber or optical fiber bundle and the light source 120 is a laser or filtered broad spectrum light source (e.g., lamp). The detection/analysis subsystem 114 includes a detector 124, an analyzer unit 126 and a signal conduit 128 interconnecting the detector 124 and the analyzer 126. The detector 124 can be located in the tip 104 as shown in Figure 1A, in the probe 102 as shown in Figure IB or in the analyzer unit 126 as shown in Figure 1C. The output signal forwarded to the analyzer 126 can be optical and/or acoustic, if the detector 124 is located in the analyzer 126 or electrical, if the detector 124 is located in the probe 104. [0036] Referring now to Figures 1D-G, several probe tip and optical fiber arrangements are shown. Looking at Figure ID, the light conduit 122 is a single optical fiber, while the signal conduit 128 includes six optical fibers surrounding the light conduit 122 for a cylindrical probe 102 and circular probe tip 104. Looking at Figure IE, the light conduit 122 includes four fibers and the signal conduit 128 includes four optical fibers surrounding the light conduit 122 arranged side by side for an oval shaped probe 102 and tip 104. Looking at Figure IF, the light conduit 122 includes four fibers and the signal conduit 128 includes four optical fibers surrounding the light conduit 122 arranged intermixed for a rectangular probe 102 and probe tip 104. Looking at Figure 1G, the light conduit 122 includes one fiber and the signal conduit 128 includes tliree optical fibers surrounding the light conduit 122 for a triangular probe 102 and probe tip 104.
[0037] Looking at Figure 1H, the system 100 works by placing the probe tip 104 in contact with the surface tissue 106 over the vein 108. hi this figure, the probe 102 also includes a finger grip 103 for better control of the probe tip placement. The light delivery system 112 is then activated, turned on, and excitation radiation travels from the light source 120 through the light conduit 122 and out the light outlet 116 in the probe tip 104. The excitation radiation then propagates through the surface tissue 106, a relatively thin tissue layer, and into the vein 108 where a response signal is produced. The response signal then enters the signal port 118 where it is either detected by the detector 124 in the probe 102 or the probe tip 104 or travels down the signal conduit 128 to the detector 124 associated with the analyzer unit 126. The detector 124 converts the signal into a detector response and the analyzer converts the response into a concentration of a blood component and/or a value of a blood parameter. [0038] Referring now to Figure 2, a second embodiment of an apparatus of this invention, generally 200, is shown to include a first teeth engaging side section 202a, a second teeth engaging side section 202b, a first and a second downwardly extending sections 204a&b and a middle section 206 bridging the two downwardly extending sections 204a&b adapted to contact the underside of a patient's tongue (not shown). The middle section 206 includes two emitters 208a&b and two receivers 210a&b. Extending from the two emitters 208a&b and the two detectors 210a&b are light conduits 212a&b, shown here as two optical fibers 214a&b terminating at the emitters 208a&b, and signal conduits (light or sound) 216a&b, also shown here as to optical fibers 218a&b terminating at the receivers. The light conduits 212a&b are connected to a light source 220, while the signal conduits 216a&b are connected to a detector/analyzer 222. THEORETICAL SECTION OF THE INVENTION
[0039] Most tissues are strongly scattering media in the visible and near-IR spectral range. Three major optical parameters are responsible for distribution of light in tissues: 1) the absorption coefficient (μ ; 2) the scattering coefficient (μs); and 3) the effective attenuation (μeff) coefficient. The effective attenuation coefficient (μeff) is related to μa, μs, and the anisotropy factor (g) thusly:
(1) where μs(l-g) is the reduced scattering coefficient, μs ' [1]. Light penetration depth in tissues is defined as l/μeff. Absorption and reduced scattering coefficients of tissues are moderate in the visible spectral range and low in the near-IR spectral range (from 600 to 1600 nm), which results in deeper penetration of visible and especially near-IR radiation compared with that of other parts of the spectrum. Application of visible or near-IR radiation will allow insignificant attenuation of light in the thin tissues between the vein on the underside of the tongue and the probe.
[0040] Hemoglobin has a high absorption coefficient in the visible and near-IR spectral range that is dependent on hemoglobin oxygen saturation (the ratio of oxyhemoglobin to total hemoglobin (THb) [1]. The blood absorption coefficient, μa [blood], is related to oxyhemoglobin concentration (C[oxy]) and deoxyhemoglobin concentration (C[deoxy]) as follows: μa [blood] = C[oxy] x K[oxy] + C[deoxy] x K[deoxy] (2) where K[oxy] and K[deoxy] are Icnown values of extinction coefficients of oxy- and deoxyhemoglobin at a given wavelength. Since K[oxy] = K[deoxy] = K at isosbestic wavelengths and THb = C[oxy] + C[deoxy], one can measure hemoglobin in the veins because: μa [blood] = THb x K (3)
[0041] The tissue between the vein on the underside of the tongue and the probe is optically thin in the visible and near IR spectral ranges because: μeff x L « 1 due to relatively low μeff (- 1 - 5 cm"1) and small L (-0.01-0.02 cm), hi contrast, blood in the vein is optically thick: u-eff, biood x L biood >:> 1 because μeffιbι0od *s high (-10 cm"1) and L is about 2 to 3 mm. Attenuation is the tissue is insignificant and all signal will be from blood. The signal from the deeper tissues will not be significant due to strong light attenuation by blood in the vein. EXPERIMENTAL DATA OF THIS INVENTION [0042] Figure 3 shows diffuse reflectance spectra obtained from sheep blood at different total hemoglobin concentration (THb) through the cylindrical wall (thickness 0.8 mm) of a 10-mL syringe. Blood with an initial THb of 8.2 g/dL, oxygenation of 56%, and volume of 5 mL was progressively diluted with saline with increments of 0.5 mL. The final concentration was 4.1 g/dL. The spectra were obtained with a portable (pocket size) spectrometer (range from 600 to 1180 nm) operated with a laptop computer. This range included the isobestic wavelength of 805 nm, where oxy- and deoxyhemoglobin have the same absorption coefficient. Therefore, variations of blood oxygenation do not influence the accuracy of THb measurement at this wavelength. The sample was irradiated by a tungsten lamp (the lamp and its power supply are compact: pocket size; designed for this spectrometer) through a reflection probe combining one 0.4-mm illumination fiber and six 0.4-mm fibers around it for detection of the reflectance signal. The system was calibrated with a reflectance standard with 25% reflectivity. The standard is being widely used for calibration of optical spectroscopic instruments in a wide spectral range that includes ultraviolet (UV), visible, and near infra-red (near-IR) spectral ranges.
[0043] The diffuse reflectance signal is due to light scattering from red blood cells in blood. All spectra had: (1) a minimum at 760 nm due to the absorption peak (maximum of absorption) at this wavelength for deoxygenated hemoglobin and (2) low intensity at 600 nm due to strong absorption by hemoglobin. The spectra were dependent on THb. In this geometry of irradiation, the reflectance signal first increased and then decreased with dilution. [0044] Since the tissues between the blood circulating in the tongue vein and the probe are very thin (01.-0.2 mm), they are optically thin in the visible and near-IR spectral ranges due to low tissue absorption. Therefore, the reflectance signal from blood circulating in the vein is not influenced by variation of optical properties of the tissue. Figure 4 shows representative reflectance spectra measured: (1) in vitro from blood; (2) in vivo from the two big veins (VI and V2) on underside of the tongue of a healthy volunteer; and (3) at three locations: right, left and middle part of the underside of the tongue (Tl, T2, and T3, respectively). It is clearly seen that the spectra measured from the veins are similar to that of blood. As in pure blood, the spectra have minimum values at 760 nm and low intensity at 600 nm. The spectra measured from the tongue tissue are different from that of pure blood: high intensity at 600 nm and no minimum at 760 nm. [0045] The reflectance signal at a given THb and oxygenation is dependent on wavelength and the reflectance probe configuration. We performed experiments with different probes in a wide spectral range with two spectrometers operating in the range from 520 to 1180 nm and
Figure imgf000011_0001
[0046] Figure 5 shows the reflectance signal at 805 nm vs. THb for the spectra presented in Figure 3. The signal is linearly dependent on THb from 4.1 to 6.3 g/dL. [0047] Another set of experiments was performed with circulating centrifuged sheep blood. Typically, THb of sheep blood (6-9 g/dL) is lower than that of human blood (ll-16 g/dL) . By using the centrifuge one can obtain blood with THb up to 14-16 g/dL (typical for human blood). To simulate the gap of 0.1 -0.2 mm between the veins and the probe, we used a thin (0.15 mm) microscopic glass slide cover. Figure 6A and 6B show reflectance spectra obtained from blood (initial THb of 14.1 g/dL) with the two spectrometers, respectively. Both spectra were measured simultaneously by using a fiber-optic splitter attached to the detection fibers of the probe. One can see that the spectra are dependent on THb in both spectral ranges. Reflectance signals are presented as a function of THb for 805 and 1300 nm in Figure 7A. The dependence was linear up to approximately 8 and 9 g/dL for the wavelengths of 805 and 1300 nm, respectively. At 1450 nm, it was linear up to 10 g/dL as shown in Figure 7B.
[0048] Blood dilution lowers both the absorption coefficient (which is proportional to THb up to 1150 nm) and the scattering coefficient (which is proportional to hematocrit). In general, total diffuse reflection (all photons that are reflected from tissue due to scattering) decreases with the absorption coefficient and increases with scattering coefficient and should be constant for tissues if both these coefficients decrease proportionally. However, spatial distribution of the diffusively reflected light varies with blood dilution. Therefore, the reflection signal from blood is strongly dependent on the distance between the irradiation and detection fiber. To accurately measure THb and hematocrit, one needs to find a configuration of the probe with optimal distance between the irradiation and detection fibers. We performed a set of experiments with aprobe that has a 3-mm distance between irradiation and detection fibers. Gradual increase of the reflectance signal was obtained in a wide spectral range from 600 to 1180 nm as shown in Figure 7A&B with blood dilution. Figure 8A&B demonstrated the increase of the reflectance signal with dilution at 805 and 1130 nm, respectively. The increase of the reflectance signal with THb is due to deeper penetration of light in blood (decrease of blood effective attenuation coefficient). More photons can reach the detection fiber (separated by 3 mm from the irradiation fiber) at lower effective attenuation coefficient.
[0049] The obtained results demonstrate that one can measure THb and hematocrit with this technique if optimum probe configuration and wavelengths are used. Aprobe with detection fibers aligned on one or two opposite sides from the irradiation fiber (and along the vein) may provide very accurate measurement because the value of the signals measured at different distances from the irradiation fiber can be used in the calculation of THb and hematocrit. [0050] To find optimal wavelength we measured total diffuse reflectance R,j of blood with an integrating sphere and both spectrometers. The studies with integrating spheres are being used for measurement of optical properties of absorbing and scattering media. Sheep blood was centrifuged and gradually diluted as described above. The integrating sphere allowed to detect all photons reflected back due scattering by blood cells. Figure 9A-B shows spectra obtained from sheep venous blood (initial THb = 14.8 g/dL; oxygenation = 57%; Hct = 44.4%o) at different THb concentrations. Decrease of THb resulted in different changes in different part of the spectra. One can see that the oxygenation gradually increased (the maximum at 760 nm is less pronounced at lower THb) due to penetration of oxygen in blood during dilutions. However, variations of the oxygenation in blood do not affect accuracy of measurements, if we use isosbestic wavelengths for analysis of the data and calibration of the system.
[0051] We plotted Rd vs. THb at two isobestic wavelengths: 805 and 1300 nm as shown in Figure 10 A. We also calculated the ratio Rd(1300nm)/Rd(805nm) and obtained a linear dependence in the whole range of THb (from3.6 to 14.8 g/dL) with the correlation coefficient of R2 = 0.998 as shown in Figure 10B. This demonstrates good correlation between the ratio Rd(1300nm)/Rd(805nm) and THb and indicates that this ratio can be used for accurate measurement of THb. The linear dependence was obtained at these wavelength because: (1) Rd - μs ' / μa at relatively high μa typical of blood and (2) μa at 805 nm is linearly proportional to THb (negligible water absorption) and is constant at 1300 nm (negligible Hb absorption). This combination results in the linear dependence of R^(1300nm)/Rd(805nm) vs. THb. [0052] One can use these two wavelengths and this algorithm to accurately measure THb. We designed, built, and tested a compact inexpensive laser diode based-system operation at two wavelengths: 1300 nm and 790 nm (which is close to 805 nm). Although the use of integrating spheres (irradiation and detection window of about 1 cm) is possible for the noninvasive blood analysis, it is easier and more practical to use probes with smaller size. [0053] We used a probe with one 0.4-mm fiber for illumination and six 0.4-mm fibers around it for detection. Same blood samples that we used in the studies with the integrating sphere were irradiated in a plastic cuvette (blood volume 0.3 mL; thiclcness - 4 mm) through a thin plastic film (thickness - 0.13 mm) simulating thin tissue between the vein and the surface of the underside of the tongue. Figure 11 A shows the dependence of the reflectance signal at 790 and 1300 nm vs. THb that is similar to Rd vs. THb at the two isobestic wavelengths (805 and 1300 nm). Although the dependence of the ratio R(1300nm)/R(790nm) vs. THb is not linear as shown in Figure 11B, it can be used for calibration of the system. The dependence is not linear because of the following two reasons: the detection fibers collect light scattered almost backward (not in all directions as in the case of the integrating sphere) and 790 nm is not exactly at the isobestic point.
[0054] All references cited herein are incorporated by reference. While this invention has been described fully and completely, it should be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described. Although the invention has been disclosed with reference to its preferred embodiments, from reading this description those of skill in the art may appreciate changes and modification that may be made which do not depart from the scope and spirit of the invention as described above and claimed hereafter.

Claims

CLAIMSWe claim:
1. A method for noninvasive analysis of at least one blood component comprising the steps of: irradiating blood in a big vein associated with an underside of a patient's tongue with radiation having at least one frequency or wavelength; detecting a response from blood irradiated in the irradiating step; calculating a concentration of a blood component, a value of a blood parameter or a mixture or combination thereof.
2. The method of claim 1, further comprising the step of: displaying at least one result from the calculating step.
3. The method of claim 1 , further comprising the step of: utilizing one or a combination of techniques selected from the group consisting of
> reflectance technique, confocal technique, scanning confocal technique, polarization
I- techniques, interferometry, optoacoustics, low coherence interferometry and reflectometry,
! techniques based on speckle measurements, fluorescence technique, Raman scattering ϊ technique, and two or multi-photon techniques
4. The method of claim 1, wherein the radiation is in a spectral range from about 200 nanometers to about 20 microns.
I 5. The m ethod o f claim 1 , w herein t he r esponse c orresponds t o a c oncentration o f
I hemoglobin in the blood and the radiation is in a spectral wavelengths selected from the group
5 consisting of 548 nm, 568 nm, 587 nm, and 805 nm (the isosbestic points) and spectral ranges
1- from about 400 nm to about 640 nm and above about 1120 nm where absorption coefficients
5 of oxy- and deoxygenated blood are close to each other.
L
6. The method of claim 1 , wherein the response corresponds to hematocrit.
7. The method of claim 1, wherein the response corresponds to a concentrations of hemoglobin and/or glycosylated hemoglobin, where the detection and quantitation of hemoglobin and/or glycosylated hemoglobin.
8. The m ethod o f c laim 1 , w herein t he r esponse c orresponds t o a c oncentration o f glucose.
9. The m ethod o f c laim 1 , w herein t he r esponse c orresponds t o a c oncentration o f cholesterol.
10. The method of claim 1, wherein the response corresponds to a concentrations of oxyhemoglobin, deoxy-hemoglobin, and carboxy-hemoglobin.
11. The method of claim 1, wherein the response corresponds to a concentration of an exogenous substance.
12. The method of claim 1, wherein the exogenous substance is selected from the group consisting of a drug, a dye or other reporter in molecular state or a particle made of liquid, gas, or solid material including polymer, metal, semiconductor, dielectric, or a combination of liquid, gas, or solid materials, and a layered structure.
13. The method of claim 1, wherein the exogenous substance selected from the group consisting of indocyanine green and Evans blue.
14. The method of claim 1 , wherein the exogenous substance that are particles with a size from about 0.1 nanometer to about 10 microns.
15. The method of claim 1 , wherein the radiation is microwave radiation.
16. The method of claim 1 , wherein the radiation is radiofrequency radiation.
17. The method of claim 1, wherein the radiation is ultrasound radiation.
18. The method of claim 1, wherein the radiation is low-frequency electromagnetic radiation.
19. The method of claim 1 , further comprising: using a static electric or magnetic field.
20. The method of claim 1, further comprising using a hybrid technique for irradiation and detection.
21. The method of claim 1, wherein the radiation comprises one, two, or many wavelengths (frequencies).
22. An apparatus for noninvasive blood analysis comprising: a probe including a tip having a radiation outlet and a response inlet, where the probe tip is adapted to be placed in proximity to or in contact with a surface of a tissue over a big vein associated with an underside of a patient's tongue; a light generation/delivery system including a light source capable of generating at least one frequency of light, and a light conduit intercomiecting the light source with the radiation outlet, where the system is adapted to deliver radiation to blood in the big vein; and a detector/analyzer system including a detector adapted to detect a response from the irradiated blood via the response inlet and an analyzer adapted to convert the detected response into a concentration of a blood component and/or a value of a parameter of the blood.
23. An apparatus for noninvasive blood analysis comprising: right side and left side sections adapted to engage one or more teeth on each of a right side and left side of a patient's jaw, two transitions section extending downwardly from each of the side sections, a middle section interposed between the two transitions sections adapted to be proximate to or in contact with an underside of a patient's tongue, where the middle section includes; a emitter, and a receiver, where the emitter and the receiver are proximate or in contact with a surface of a tissue over a big vein associated with an underside of the patient's tongue; a light generation/delivery system including a light source capable of generating at least one frequency of light, and a light conduit intercomiecting the light source with the radiation outlet, where the system is adapted to deliver radiation to blood in the big vein; and a detector/analyzer system including a detector adapted to detect a response from the irradiated blood via the response inlet and an analyzer adapted to convert the detected response into a concentration of a blood component and/or a value of a parameter of the blood.
24. The apparatus of claim 24, further comprising: a plurality of emitters and receivers, located in pairs on a right hand side and a left side of the middle section.
25. The apparatus of claims 22, 23 or 24, further comprising: a display adapted to display the response (raw data) or converted response (refined data)
26. The apparatus of claims 22, 23 or 24, wherein the radiation is the spectral range from about 200 nanometers to about 20 microns.
27. The apparatus of claims 22, 23 or 24, further comprises: one or a combination of techniques selected from the group consisting of reflectance technique, confocal technique, scanning confocal technique, polarization techniques, interferometry, optoacoustics, low coherence interferometry and reflectometry, techniques based on speckle measurements, fluorescence technique, Raman scattering technique, and two or multi-photon techniques
L 28. The apparatus of claims 22, 23 or 24, wherein the response corresponds to a
. concentration of hemoglobin in the blood and the radiation is in a spectral wavelengths
\ selected from the group consisting of 548 nm, 568 nm, 587 nm, and 805 nm (the isosbestic
\ points) and spectral ranges from about 400 nm to about 640 nm and above about 1120 nm
> where absorption coefficients of oxy- and deoxygenated blood are close to each other.
I 29. The apparatus of claims 22, 23 or 24, wherein the response corresponds to hematocrit.
1 30. The apparatus of claims 22, 23 or 24, wherein the response corresponds to a
2 concentrations o f h emoglobin a nd/or g lycosylated h emoglobin, w here t he d etection and
3 quantitation of hemoglobin and/or glycosylated hemoglobin.
1 31. The apparatus of claims 22, 23 or 24, wherein the response corresponds to a
2 concentration of glucose.
1 32. The apparatus of claims 22, 23 or 24, wherein the response corresponds to a
2 concentration of cholesterol.
1 33. The apparatus of claim 22, wherein the response corresponds to a concentrations of
2 oxy-hemoglobin, deoxy-hemoglobin, and carboxy-hemoglobin.
1 34. The apparatus of claims 22, 23 or 24, wherein the response corresponds to a
2 concentration of an exogenous substance.
1 35. The apparatus of claims 22, 23 or 24, wherein the exogenous substance is selected
2 from the group consisting of a drug, a dye or other reporter in molecular state or a particle
3 made of liquid, gas, or solid material including polymer, metal, semiconductor, dielectric, or
4 a combination of liquid, gas, or solid materials, and a layered structure.
1 36. The apparatus of claims 22, 23 or 24, wherein the exogenous substance selected from
2 the group consisting of indocyanine green and Evans blue.
37. The apparatus of claims 22, 23 or 24, wherein the exogenous substance that are particles with a size from about 0.1 nanometer to about 10 microns.
38. The apparatus of claims 22, 23 or 24, wherein the radiation is microwave radiation.
39. The apparatus of claims 22, 23 or 24, wherein the radiation is radiofrequency radiation.
40. The apparatus of claims 22, 23 or 24, wherein the radiation is ultrasound radiation.
41. The apparatus of claims 22, 23 or 24, wherein the radiation is low-frequency electromagnetic radiation.
42. The apparatus of claims 22, 23 or 24, further comprising:
> a static electric or magnetic field.
43. The apparatus of claims 22, 23 or 24, further comprising a hybrid technique for I irradiation and detection.
44. The apparatus of claims 22, 23 or 24, wherein the radiation comprises one, two, or
) many wavelengths (frequencies).
PCT/US2004/012758 2003-04-24 2004-04-26 Noninvasive blood analysis by optical probing of the veins under the tongue WO2004096082A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2004233870A AU2004233870B2 (en) 2003-04-24 2004-04-26 Noninvasive blood analysis by optical probing of the veins under the tongue
EP04750643A EP1620002B1 (en) 2003-04-24 2004-04-26 Noninvasive blood analysis by optical probing of the veins under the tongue
US10/554,149 US7430445B2 (en) 2003-04-24 2004-04-26 Noninvasive blood analysis by optical probing of the veins under the tongue
AT04750643T ATE539674T1 (en) 2003-04-24 2004-04-26 NON-INVASIVE BLOOD ANALYSIS BY OPTICAL PROBING OF THE VEINS UNDER THE TONGUE
US12/150,108 US8352005B2 (en) 2003-04-24 2008-04-24 Noninvasive blood analysis by optical probing of the veins under the tongue

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46513403P 2003-04-24 2003-04-24
US60/465,134 2003-04-24

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10554149 A-371-Of-International 2004-04-26
US12/150,108 Continuation US8352005B2 (en) 2003-04-24 2008-04-24 Noninvasive blood analysis by optical probing of the veins under the tongue

Publications (2)

Publication Number Publication Date
WO2004096082A2 true WO2004096082A2 (en) 2004-11-11
WO2004096082A3 WO2004096082A3 (en) 2004-12-29

Family

ID=33418191

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/012758 WO2004096082A2 (en) 2003-04-24 2004-04-26 Noninvasive blood analysis by optical probing of the veins under the tongue

Country Status (5)

Country Link
US (2) US7430445B2 (en)
EP (1) EP1620002B1 (en)
AT (1) ATE539674T1 (en)
AU (1) AU2004233870B2 (en)
WO (1) WO2004096082A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2015053A1 (en) * 2006-03-24 2009-01-14 Arkray, Inc. Method for determination of glycosylated hemoglobin level and apparatus for determination of the level
WO2007047198A3 (en) * 2005-10-12 2009-04-30 Thomas Perez Method and apparatus for sublingual application of light to blood
WO2018185056A1 (en) * 2017-04-05 2018-10-11 Koninklijke Philips N.V. Sublingual patient monitoring
US10209178B2 (en) 2013-01-31 2019-02-19 Universidade Do Minho Optical system for parameter characterization of an element of body fluid or tissue

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8135450B2 (en) * 2006-01-20 2012-03-13 Esenaliev Rinat O Noninvasive glucose sensing methods and systems
US9283288B2 (en) 2006-02-24 2016-03-15 Medibeacon, Inc. Methods of using optical agents
EP2069633A4 (en) * 2006-09-14 2017-05-03 Valentin Korman Regression and erosion measurement system and method
US10231656B2 (en) 2007-04-11 2019-03-19 Noninvasix, Inc. Systems and methods for measuring oxygenation
US10226206B2 (en) 2007-04-11 2019-03-12 The Board Of Regents Of The University Of Texas System Systems and methods for measuring neonatal cerebral oxygenation
US20090216096A1 (en) * 2007-12-31 2009-08-27 Nellcor Puritan Bennett Llc Method and apparatus to determine skin sterol levels
JP4618341B2 (en) * 2008-06-26 2011-01-26 ソニー株式会社 A method for measuring the amount of substances in a living body using coherent anti-Stokes Raman scattering light
WO2010129258A2 (en) 2009-04-27 2010-11-11 Mallinckrodt Inc. Tissue sealant compositions, vascular closure devices, and uses thereof
US20110082711A1 (en) 2009-10-06 2011-04-07 Masimo Laboratories, Inc. Personal digital assistant or organizer for monitoring glucose levels
US9055869B2 (en) 2011-10-28 2015-06-16 Covidien Lp Methods and systems for photoacoustic signal processing
US8886294B2 (en) 2011-11-30 2014-11-11 Covidien Lp Methods and systems for photoacoustic monitoring using indicator dilution
US9131852B2 (en) 2011-12-05 2015-09-15 Covidien Lp Methods and systems for photoacoustic monitoring using indicator dilution
US9186068B2 (en) 2011-12-05 2015-11-17 Covidien Lp Methods and systems for photoacoustic monitoring using hypertonic and isotonic indicator dilutions
CN108261183A (en) * 2012-02-17 2018-07-10 药物影像股份有限公司 For monitoring the composition of biometric indicators and method
US8885155B2 (en) 2012-04-30 2014-11-11 Covidien Lp Combined light source photoacoustic system
US9380981B2 (en) 2013-03-15 2016-07-05 Covidien Lp Photoacoustic monitoring technique with noise reduction
AU2014339082B2 (en) 2013-10-22 2018-11-08 Jochen Friedemann Improved transcutaneous organ function measurement
US11077211B2 (en) 2013-11-11 2021-08-03 Medibeacon Inc. Compositions and methods for assessing gut function
EP3166494A4 (en) 2014-07-08 2018-03-21 The Board of Regents of The University of Texas System Systems and methods for measuring fetal cerebral oxygenation
US10231667B2 (en) 2014-10-31 2019-03-19 Koninklijke Philips N.V. Non-invasive dehydration monitoring
AU2016233575A1 (en) 2015-03-14 2017-07-13 The Board Of Regents Of The University Of Texas System Systems and methods for measuring neonatal cerebral oxygenation
WO2016183351A1 (en) 2015-05-12 2016-11-17 Medibeacon Inc. Compositions and methods for assessing eye vasculature
WO2017111623A1 (en) 2015-12-24 2017-06-29 Sensorflo Limited A non-invasive sensing system
US10493204B2 (en) * 2016-11-11 2019-12-03 Imam Abdulrahman Bin Faisal University Aspirator syringe with blood detector
JP7258751B2 (en) * 2016-12-20 2023-04-17 コーニンクレッカ フィリップス エヌ ヴェ patient monitoring
MX2019009040A (en) 2017-01-30 2019-11-11 Medibeacon Inc Method for non-invasive monitoring of fluorescent tracer agent with diffuse reflection corrections.
KR102408951B1 (en) 2017-09-18 2022-06-13 삼성전자주식회사 Apparatus and method for estimating glucose exposure, Apparatus and method for generating glucose exposure estimation model
MY197859A (en) 2017-10-27 2023-07-20 Medibeacon Inc Compositions and systems for renal function determination
US11590244B2 (en) 2017-10-27 2023-02-28 Medibeacon Inc. Methods for renal function determination
KR20200007778A (en) 2017-11-20 2020-01-22 메디비콘 아이엔씨. Method for preparing and analyzing fluorescent compound in plasma
WO2019143676A1 (en) * 2018-01-16 2019-07-25 Mayo Foundation For Medical Education And Research System and method for rapid assessment of renal function
CN109044366B (en) * 2018-07-25 2021-06-04 广东海尔斯激光医疗科技有限公司 Method for detecting glycosylated hemoglobin and blood oxygen saturation and optical fingertip detector
CN111436947B (en) 2019-01-16 2022-12-23 麦迪贝肯有限公司 Two-piece sensor assembly and method of using same
EP4041235A1 (en) 2019-10-10 2022-08-17 Medibeacon Inc. Anodic oxidation of 5-aminouracil
US11701035B2 (en) 2019-10-28 2023-07-18 Bruce M. Landy Noninvasive blood glucose detector and method using IR
US11191460B1 (en) 2020-07-15 2021-12-07 Shani Biotechnologies LLC Device and method for measuring blood components

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4890619A (en) 1986-04-15 1990-01-02 Hatschek Rudolf A System for the measurement of the content of a gas in blood, in particular the oxygen saturation of blood

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028933A (en) 1974-02-15 1977-06-14 The Board Of Trustees Of Leland Stanford Junior University Acoustic microscope
US4167331A (en) * 1976-12-20 1979-09-11 Hewlett-Packard Company Multi-wavelength incremental absorbence oximeter
FR2405485A1 (en) 1977-10-07 1979-05-04 Thomson Csf ULTRASONIC VISUALIZATION SYSTEM OF A THIN SECTION OF A BODY
US4255971A (en) 1978-11-01 1981-03-17 Allan Rosencwaig Thermoacoustic microscopy
US4267732A (en) 1978-11-29 1981-05-19 Stanford University Board Of Trustees Acoustic microscope and method
US4385634A (en) 1981-04-24 1983-05-31 University Of Arizona Foundation Radiation-induced thermoacoustic imaging
US4430897A (en) 1981-05-14 1984-02-14 The Board Of Trustees Of The Leland Stanford University Acoustic microscope and method
US4594662A (en) 1982-11-12 1986-06-10 Schlumberger Technology Corporation Diffraction tomography systems and methods with fixed detector arrays
EP0178653B1 (en) 1984-10-16 1990-02-28 Fuji Photo Film Co., Ltd. Acoustooptic image formation
US4710030A (en) 1985-05-17 1987-12-01 Bw Brown University Research Foundation Optical generator and detector of stress pulses
DE3743920A1 (en) 1986-12-26 1988-07-14 Olympus Optical Co ENDOSCOPE DEVICE
JPH0629196B2 (en) 1987-12-01 1994-04-20 甲子郎 梅村 Physiological action enhancer for tumor treatment by ultrasound
DE3741201A1 (en) 1987-12-02 1989-06-15 Schering Ag ULTRASONIC PROCESS AND METHOD FOR IMPLEMENTING IT
US5141331A (en) 1988-02-19 1992-08-25 Oscar Oehler Ultrasonic temperature measurement and uses in optical spectroscopy and calorimetry
JP2685482B2 (en) 1988-04-08 1997-12-03 株式会社日立製作所 Method and apparatus for analyzing particulate matter
JPH01308544A (en) 1988-06-06 1989-12-13 Sumitomo Electric Ind Ltd Body cavity laser operation apparatus
DE3842916C1 (en) 1988-12-21 1990-02-01 Messerschmitt-Boelkow-Blohm Gmbh, 8012 Ottobrunn, De
US5596986A (en) 1989-03-17 1997-01-28 Scico, Inc. Blood oximeter
US5421337A (en) 1989-04-14 1995-06-06 Massachusetts Institute Of Technology Spectral diagnosis of diseased tissue
WO1990013333A1 (en) 1989-05-03 1990-11-15 Intra-Sonix, Inc. Instrument and method for intraluminally relieving stenosis
US5136172A (en) 1989-08-16 1992-08-04 Hitachi, Ltd. Method and apparatus for detecting photoacoustic signal
JP2798450B2 (en) * 1989-12-08 1998-09-17 株式会社日立製作所 Biological measurement device
US5487390A (en) 1990-10-05 1996-01-30 Massachusetts Institute Of Technology Gas-filled polymeric microbubbles for ultrasound imaging
US5254112A (en) 1990-10-29 1993-10-19 C. R. Bard, Inc. Device for use in laser angioplasty
DE59207599D1 (en) * 1991-03-25 1997-01-16 Andreas Prof Dr Med Hoeft Device and method for determining cardiac output
US6485413B1 (en) 1991-04-29 2002-11-26 The General Hospital Corporation Methods and apparatus for forward-directed optical scanning instruments
DE4128744C1 (en) 1991-08-29 1993-04-22 Siemens Ag, 8000 Muenchen, De
WO1993006780A1 (en) 1991-10-03 1993-04-15 The General Hospital Corporation Apparatus and method for vasodilation
US5269309A (en) 1991-12-11 1993-12-14 Fort J Robert Synthetic aperture ultrasound imaging system
US5398685A (en) 1992-01-10 1995-03-21 Wilk; Peter J. Endoscopic diagnostic system and associated method
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5348002A (en) 1992-04-23 1994-09-20 Sirraya, Inc. Method and apparatus for material analysis
US5161125A (en) 1992-05-05 1992-11-03 The United States Of America As Represented By The Secretary Of The Navy Radiation selective system for target range and imaging readout
US5384003A (en) * 1992-08-24 1995-01-24 Minnesota Mining And Manufacturing Company Dispenser for tapes and similar web materials incorporating a cutting and delayed feed mechanism
US5348003A (en) * 1992-09-03 1994-09-20 Sirraya, Inc. Method and apparatus for chemical analysis
US5403590A (en) 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
US5614502A (en) 1993-01-15 1997-03-25 The General Hospital Corporation High-pressure impulse transient drug delivery for the treatment of proliferative diseases
US5417653A (en) 1993-01-21 1995-05-23 Sahota; Harvinder Method for minimizing restenosis
US5341805A (en) * 1993-04-06 1994-08-30 Cedars-Sinai Medical Center Glucose fluorescence monitor and method
US5588428A (en) 1993-04-28 1996-12-31 The University Of Akron Method and apparatus for non-invasive volume and texture analysis
GB9312327D0 (en) 1993-06-15 1993-07-28 British Tech Group Laser ultrasound probe and ablator
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5349954A (en) 1993-07-23 1994-09-27 General Electric Company Tumor tissue characterization apparatus and method
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5599712A (en) 1993-10-15 1997-02-04 University Of Pittsburgh Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
FR2712697B1 (en) 1993-11-19 1995-12-15 Commissariat Energie Atomique Elementary analysis method by optical emission spectrometry on plasma produced by laser in the presence of argon.
FR2715731B1 (en) 1994-01-31 1996-04-26 Aerospatiale Method for predictive determination of the breaking load of a structure.
US5444541A (en) 1994-02-16 1995-08-22 Eastern Washington University Methods for photoacoustically analyzing chemicals and chemical reactions using photoactive particle-emitting compounds
JP3134144B2 (en) * 1994-03-11 2001-02-13 日本光電工業株式会社 Physiological detector
TW275570B (en) 1994-05-05 1996-05-11 Boehringer Mannheim Gmbh
US5836905A (en) 1994-06-20 1998-11-17 Lemelson; Jerome H. Apparatus and methods for gene therapy
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5602894A (en) 1994-08-04 1997-02-11 Bardash; Michael J. Three-dimensional imaging system using laser generated ultrashort x-ray pulses
WO1996029000A1 (en) 1995-03-23 1996-09-26 Philips Electronics N.V. Device for carrying out optical measurements in turbid media
US5582578A (en) 1995-08-01 1996-12-10 Duke University Method for the comminution of concretions
US5840023A (en) 1996-01-31 1998-11-24 Oraevsky; Alexander A. Optoacoustic imaging for medical diagnosis
US6309352B1 (en) 1996-01-31 2001-10-30 Board Of Regents, The University Of Texas System Real time optoacoustic monitoring of changes in tissue properties
US5615675A (en) 1996-04-19 1997-04-01 Regents Of The University Of Michigan Method and system for 3-D acoustic microscopy using short pulse excitation and 3-D acoustic microscope for use therein
US5944687A (en) 1996-04-24 1999-08-31 The Regents Of The University Of California Opto-acoustic transducer for medical applications
US5713356A (en) 1996-10-04 1998-02-03 Optosonics, Inc. Photoacoustic breast scanner
US5897494A (en) 1997-01-31 1999-04-27 The Board Of Trustees Of The University Of Arkansas Vibrometer
US6165440A (en) 1997-07-09 2000-12-26 Board Of Regents, The University Of Texas System Radiation and nanoparticles for enhancement of drug delivery in solid tumors
US6125290A (en) 1998-10-30 2000-09-26 Medtronic, Inc. Tissue overgrowth detector for implantable medical device
US5924986A (en) 1997-09-10 1999-07-20 Acuson Corporation Method and system for coherent ultrasound imaging of induced, distributed source, bulk acoustic emissions
US5941821A (en) 1997-11-25 1999-08-24 Trw Inc. Method and apparatus for noninvasive measurement of blood glucose by photoacoustics
US5977538A (en) 1998-05-11 1999-11-02 Imarx Pharmaceutical Corp. Optoacoustic imaging system
US6064898A (en) 1998-09-21 2000-05-16 Essential Medical Devices Non-invasive blood component analyzer
US5902237A (en) 1998-10-26 1999-05-11 Hood Laboratories Method of operating acoustic imaging
US6175759B1 (en) 1999-06-28 2001-01-16 The United States Of America As Represented By The Secretary Of The Air Force Contrast agent for multispectral infrared transillumination and fluorescence of turbid media
AU6894500A (en) 1999-08-06 2001-03-05 Board Of Regents, The University Of Texas System Optoacoustic monitoring of blood oxygenation
US6725073B1 (en) 1999-08-17 2004-04-20 Board Of Regents, The University Of Texas System Methods for noninvasive analyte sensing
US6751490B2 (en) 2000-03-01 2004-06-15 The Board Of Regents Of The University Of Texas System Continuous optoacoustic monitoring of hemoglobin concentration and hematocrit
US6850789B2 (en) * 2002-07-29 2005-02-01 Welch Allyn, Inc. Combination SPO2/temperature measuring apparatus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4890619A (en) 1986-04-15 1990-01-02 Hatschek Rudolf A System for the measurement of the content of a gas in blood, in particular the oxygen saturation of blood

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047198A3 (en) * 2005-10-12 2009-04-30 Thomas Perez Method and apparatus for sublingual application of light to blood
EP2015053A1 (en) * 2006-03-24 2009-01-14 Arkray, Inc. Method for determination of glycosylated hemoglobin level and apparatus for determination of the level
EP2015053A4 (en) * 2006-03-24 2014-03-05 Arkray Inc Method for determination of glycosylated hemoglobin level and apparatus for determination of the level
US10209178B2 (en) 2013-01-31 2019-02-19 Universidade Do Minho Optical system for parameter characterization of an element of body fluid or tissue
US11435284B2 (en) 2013-01-31 2022-09-06 Universidade Do Minho Optical system for parameter characterization of an element of body fluid or tissue
WO2018185056A1 (en) * 2017-04-05 2018-10-11 Koninklijke Philips N.V. Sublingual patient monitoring

Also Published As

Publication number Publication date
AU2004233870A1 (en) 2004-11-11
EP1620002B1 (en) 2012-01-04
EP1620002A2 (en) 2006-02-01
US20060195021A1 (en) 2006-08-31
US8352005B2 (en) 2013-01-08
AU2004233870B2 (en) 2009-11-05
WO2004096082A3 (en) 2004-12-29
US20080281173A1 (en) 2008-11-13
ATE539674T1 (en) 2012-01-15
US7430445B2 (en) 2008-09-30
EP1620002A4 (en) 2007-09-19

Similar Documents

Publication Publication Date Title
US7430445B2 (en) Noninvasive blood analysis by optical probing of the veins under the tongue
US7304724B2 (en) Method and apparatus for quantification of optical properties of superficial volumes
US6630673B2 (en) Non-invasive sensor capable of determining optical parameters in a sample having multiple layers
Fantini et al. Frequency-domain multichannel optical detector for noninvasive tissue spectroscopy and oximetry
Nickell et al. Anisotropy of light propagation in human skin
EP2273914B1 (en) Method for dating a body sample
US6662031B1 (en) Method and device for the noninvasive determination of hemoglobin and hematocrit
US5137023A (en) Method and apparatus for monitoring blood analytes noninvasively by pulsatile photoplethysmography
US7307734B2 (en) Interferometric sensor for characterizing materials
KR20010040703A (en) Method and apparatus for non-invasive blood constituent monitoring
WO2001009589A1 (en) Optical sensor having a selectable sampling distance for determination of analytes
WO1993012712A1 (en) Blood constituent determination based on differential spectral analysis
JP2007083028A (en) Noninvasive inspecting apparatus
AU2002322640B2 (en) Continuous optoacoustic monitoring of hemoglobin concentration and hematocrit
Rejmstad et al. A method for monitoring of oxygen saturation changes in brain tissue using diffuse reflectance spectroscopy
KR20150050523A (en) Noninvasive measurement of analyte concentration using a fiberless transflectance probe
Ciurczak Biomedical applications of near-infrared spectroscopy
US20160296158A1 (en) Non-invasive multi-frequency oxygenation spectroscopy device using nir diffuse photon density waves for measurement and pressure gauges for prediction of pressure ulcers
Yable et al. Characterization and Optical Early Diagnosis by Diffuse Reflectance Spectroscopy
US20040009606A1 (en) Non-invasive measurement of pH
Bal et al. The determination of absorption and reduced scattering coefficients of optical phantoms using a frequency-domain multi-distance method in a non-contact manner
Rovati et al. A novel tissue oxymeter combining the multidistance approach with an accurate spectral analysis
Kinnunen Comparison of optical coherence tomography, the pulsed photoacoustic technique, and the time-of-flight technique in glucose measurements in vitro
Peng et al. Development and validation of quantitative optical index of skin blood content
Yable et al. Optical Characterization of Buruli Ulcer by Diffuse Reflectance using LEDs illumination

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006195021

Country of ref document: US

Ref document number: 10554149

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004233870

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004750643

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004233870

Country of ref document: AU

Date of ref document: 20040426

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004233870

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004750643

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10554149

Country of ref document: US